ASCRS 2025: A noninvasive approach to blepharoplasty reduces recovery time, bruising

Commentary
Video

Patricia Buehler, MD, MPH, is looking to reform blepharoplasty by reducing surgery time, recovery, and bruising by using a noninvasive approach. At ASCRS, Buehler shared a bit of background on her discovery of a new surgical technique and subsequent device development.

A game-changer in blepharoplasty

Key takeaways for optometrists:

  • Ziplyft offers a minimally invasive alternative to traditional blepharoplasty—no cautery, no sutures, less bruising.
  • Faster procedure time (under 10 minutes) makes it an efficient option for busy surgical practices.
  • Pilot study data suggests high patient satisfaction and improved surgeon experience.
  • Commercial and academic recognition signal strong potential for broader adoption.

During a visit to an exhibit on ancient Egyptian medicine, Buehler found unexpected inspiration. The exhibit showcased a method of removing excess skin using compression—twigs tied tightly to cut off blood supply, causing the skin to fall off naturally. That concept, still used in procedures like circumcision, sparked an idea that evolved into the Ziplyft, a patented device that is now changing how upper eyelid blepharoplasty is performed.

The Ziplyft device employs compression skin contouring to remove excess eyelid skin without cautery or sutures. This technique dramatically simplifies the surgical process, making it both faster and less invasive. “Instead of a 45 to 60-minute procedure, it can now be completed in less than 10 minutes,” Buehler notes.

A major innovation in Ziplyft is the inclusion of a surgical guide, which ensures greater symmetry and consistency—something often difficult to achieve in traditional, freehand blepharoplasty.

Better for patients, easier for surgeons

For patients, the benefits are clear:

  • Minimal bruising
  • No sutures or cautery
  • Faster recovery time
  • More natural-looking results

Surgeons involved in the current pilot study report that the Ziplyft technique not only reduces operative time by up to two-thirds but also alleviates the tedious steps typically involved in the procedure. With reduced patient downtime and higher satisfaction, the appeal to both providers and patients is significant.

From kitchen table to operating room

The development of the Ziplyft device began during the COVID-19 pandemic. With elective procedures on hold, the inventor and her husband, an orthopedic surgeon, began prototyping in their kitchen using chicken skin. This was followed by trials on 60 cadavers before moving into clinical use. As of now, 84 patients have undergone blepharoplasty using Ziplyft, and 4 surgeons are actively trained in its use.

Industry recognition and future outlook

The innovation has not gone unnoticed. At ASCRS 2023, the company won the Winning Pitch award for best early-stage company—marking the first time a female-founded company took the prize. The following year, they received the People’s Choice Award at Eyecelerator, further validating the device’s potential.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
© 2025 MJH Life Sciences

All rights reserved.